Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Renalytix PLC on Tuesday announced a successful fund raise alongside a narrowed annual loss.
The London-based diagnostics company said it had raised £11.8 million via a placing and subscription at 9 pence per share. In a statement on Monday, the firm said it hoped to raise at least £10 million.
Chief Executive James McCullough commented: ‘The strong demand we have seen for the fundraise supports our view that Renalytix offers investors unique access to a world-leading kidney prognostic test.’
He pointed out kidneyintelX.dkd is the only test to be approved by the US Food & Drugs Administration; granted full Medicare reimbursement at $950 per test; recommended in KDIGO clinical guidelines; available to approximately 14 million US diabetic kidney disease patients; and able to address the needs of approximately 260 million DKD patients globally.
‘We now have a strong cash and balance sheet position, we have taken positive actions to substantially reduce our monthly cash burn, and we are delivering quarter-on-quarter growth in orders, whilst also supporting a new customer launch. We believe these factors, combined, will take the company to profitability and cash flow break-even in approximately two years and that we have the potential to generate revenue of approximately $17.5 million in [financial 2027].’
Renalytix said net loss before tax narrowed to $33.5 million in the year ended June 30 from $45.6 million a year prior. Revenue slipped to $2.3 million from $3.4 million but general and administrative costs nosedived to $19.8 million from $28.7 million.
Shares in Renalytix rose 8.1% to 8.64 pence each in London on Tuesday.
Copyright 2024 Alliance News Ltd. All Rights Reserved.